Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Waldencast plc

Waldencast is a self-described global beauty and wellness multi-brand platform.

Waldencast

Waldencast is a holding company and investment fund that incubates and accelerates early stage beauty and wellness brands and helps them rapidly create scale and profitability via industry specific operational expertise. Waldencast invests in brand-led business models and goes beyond traditional incubation and acceleration to develop a collective of innovative and unique brands that place responsible entrepreneurship at the heart of its operations.  Waldencast has offices in New York and London and has an investment portfolio in North America, Europe, and Latin America.

The selection of brands to participate in the community is as much driven by the strength of the brand concept and business model as it is by our shared human and social values: sustainability, responsibility, inclusivity.  We believe brands that marry purpose, art, beauty, and design with industry and commerce to make the planet and the lives of those in it better.

Individuals that are part of the Waldencast collective are as much driven by the strength of the brands’ ideas, as it is by sharing our dreamer/maker values: ambition with humility, idealism with practicality, grit with empathy, vision with action.

We have the spirit of a challenger, a disruptor, a game-changer. We are a start-up and we intend to stay in the attitude of a start-up regardless of our success.

Costa Brazil

2024 AWARD WINNING BROW SERUM🎉

InStyle has recognized Obagi Nu-Cil™ Eyebrow Boosting Serum as the Best Brow Serum in their Best Beauty Buys 2024 product roundup! 

“I was introduced to this powerhouse brow serum by board-certified dermatologist Mona Gohara, M.D.  …So it's safe to say I'm hooked.” writes Kara Jillian Brown

Thank you to our Obagi Fam and healthcare providers for the continuous love you show our products.

Visit your Obagi provider to learn more about this great product! 
#obagi #obagimedical #obagiskincare

Read the full article here:
https://lnkd.in/giiJuG-M

We're #hiring a new Amazon Brand Manager in Greater London, England. Apply today or share this post with your network.

Congratulations to our portfolio company C16 Biosciences for this recognition!

We are excited to participate in TD Cowen’s 8th annual conference 2024 with Oliver Chen, CFA and Jonna Kim, CFA.

We’re #hiring a new Glaze North America Key Account Director in United States. Apply today or share this post with your network.

	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jul '22	Sep '22	Dec '22	Mar '23	Dec '23
net income	-1.18M -	-1.55M 31.04%	7.76M 599.99%	-19.45M 350.72%	3.02M 115.54%	2.77M 8.46%	-4.84K 100.17%	-107.15M 2,212,848.64%		-30.28M -
depreciation and amortization							12.02M -	23.16M 92.73%
deferred income tax
stock based compensation							3.15K -			1.88M -
change in working capital	63.70K -	-396.57K 722.54%	128.07K 132.29%	334.88K 161.49%	1.48M 340.77%	-694.75K 147.07%
accounts receivables
inventory
accounts payables	592.75K -	-522.00K 188.06%	-4.01K 99.23%	206.21K 5,246.34%	1.37M 565.51%	-606.01K 144.16%
other working capital	-529.05K -	125.43K 123.71%	132.07K 5.29%	128.67K 2.58%	103.68K 19.42%	-88.74K 185.59%
other non cash items	1.07M -	1.35M 26.60%	-8.40M 722.27%	19.47M 331.69%	-4.91M 125.24%	-3.66M 25.48%	12.02M 428.27%	130.31M 984.11%		28.40M -
net cash provided by operating activities	-53.68K -	-597.83K 1,013.65%	-516.80K 13.55%	352.63K 168.23%	-414.79K 217.63%	-1.59M 283.15%	24.03M 1,612.23%	46.31M 92.71%
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites	-345M -
net cash used for investing activites	-345M -
debt repayment
common stock issued	338.13M -
common stock repurchased
dividends paid
other financing activites	8.38M -			816.08K -
net cash used provided by financing activities	346.50M -			816.08K -		600K -
effect of forex changes on cash
net change in cash	1.45M -	-597.83K 141.24%	-516.80K 13.55%	1.17M 326.14%	-414.79K 135.49%	-989.25K 138.50%	24.13M 2,539.50%	46.31M 91.91%
cash at beginning of period		1.45M -	851.86K 41.24%	335.06K 60.67%	1.50M 348.81%	1.09M 27.58%	99.73 99.99%	-36.15M 36,250,062.40%	10.16M 128.11%
cash at end of period	1.45M -	851.86K 41.24%	335.06K 60.67%	1.50M 348.81%	1.09M 27.58%	99.73K 90.84%	24.13M 24,098.94%	10.16M 57.89%	10.16M 0%
operating cash flow	-53.68K -	-597.83K 1,013.65%	-516.80K 13.55%	352.63K 168.23%	-414.79K 217.63%	-1.59M 283.15%	24.03M 1,612.23%	46.31M 92.71%
capital expenditure
free cash flow	-53.68K -	-597.83K 1,013.65%	-516.80K 13.55%	352.63K 168.23%	-414.79K 217.63%	-1.59M 283.15%	24.03M 1,612.23%	46.31M 92.71%

COM:WALDENCAST

Waldencast

Last Close

3.41

21/11 21:00

Market Cap

456.93M

Beta: -

Volume Today

281.97K

Avg: -

Preview